To include your compound in the COVID-19 Resource Center, submit it here.

BeiGene falls on immune events for B cell cancer combo

BeiGene Ltd. (NASDAQ:BGNE) lost $4.59 to $91.39 Monday after reporting three immune-related events in a Phase Ib trial of zanubrutinib (BGB-3111) plus tislelizumab (BGB-A317) to treat B cell malignancies

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE